211 related articles for article (PubMed ID: 38206555)
1. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
2. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
3. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
4. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
5. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
7. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
[TBL] [Abstract][Full Text] [Related]
9. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
10. Pemigatinib: First Approval.
Hoy SM
Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
12. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
13. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
14. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
15. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
16. Infigratinib for cholangiocarcinoma.
Sadeghi S
Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract][Full Text] [Related]
18. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without
Bibeau K; Féliz L; Lihou CF; Ren H; Abou-Alfa GK
JCO Precis Oncol; 2022 Apr; 6():e2100414. PubMed ID: 35544727
[TBL] [Abstract][Full Text] [Related]
19. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
[TBL] [Abstract][Full Text] [Related]
20. PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
